Announcements
- Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
- Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
- Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
- Terns Pharmaceuticals Announces Leadership Changes
- Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
- Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
- Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
- Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
- Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
More ▼
Key statistics
On Monday, Terns Pharmaceuticals Inc (430:DUS) closed at 6.35, 103.85% above the 52 week low of 3.12 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.55 |
---|---|
High | 6.55 |
Low | 6.35 |
Bid | 6.40 |
Offer | 6.55 |
Previous close | 6.70 |
Average volume | 752.14 |
---|---|
Shares outstanding | 64.68m |
Free float | 63.53m |
P/E (TTM) | -- |
Market cap | 470.85m USD |
EPS (TTM) | -1.26 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 18:30 BST.
More ▼